PolyOrg Licenses Rights to PNA Monomers from Copenhagen Inventor Group | GenomeWeb

NEW YORK (GenomeWeb News) — PolyOrg said today that it has licensed from the Copenhagen Inventor Group the right to make and sell PNA monomers worldwide.

PNAs are oligonucleotide analogs in which the sugar-phosphate backbone of DNA is substituted by amino-ethyl-glycine backbone. They hybridize strongly to complementary DNA or RNA but are not degraded by nucleases or proteases, the company said, and they are useful for molecular biology and diagnostics applications and antisense and anti-gene therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.